Recruiting
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.
ClinicalTrials.gov IDNCT06413212
PhaseNot Applicable
Enrollment55
SponsorLiu Huang
Age18 Years
SexALL
Conditions studied
Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer
About this study
To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.
Interventions
- Diagnostic Test: Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing. — Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
Primary outcomes
- Complete Response (CR) (up to 12 months)
- Partial Response (PR) (up to 12 months)
- Progressive Disease (PD) (up to 12 months)
- Stable Disease (SD) (up to 12 months)
Eligibility information
Inclusion Criteria:
1. 18 to 75 years old, regardless of gender.
2. Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023.
3. Advanced and unresectable malignancy confirmed by biopsy diagnosis.
4. Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases.
5. Score of eastern cooperative oncology group (ECOG) is not higher than 2, ECOG≤2.
6. Anticipated survival exceed six months.
7. At least one measurable lesions (according to RECIST 1.1)
8. Resistance or intolerance to standard therapy regimens.
9. Signed informed consent form voluntarily.
Exclusion Criteria:
1. Pregnant or lactating women.
2. Have Participated other clinical trials in six months.
3. Severe liver dysfunction.
4. Severe renal dysfunction.
5. Patients with cognitive disorder, mental diseases and terrible compliance.
6. Allergic to known chemotherapeutic agents.
7. Other circumstance not suitable to participate in this trial determined by investigators.
Study locations
- Tongji Hospital, Wuhan, Hubei 430030 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.